Literature DB >> 30295187

Is very low LDL-C harmful?

Charles Faselis1, Konstantinos Imprialos2, Haris Grassos3, Andreas Pittaras4, Manolis Kallistratos4, Athanasios Manolis4.   

Abstract

BACKGROUND: Low-density Lipoprotein Cholesterol (LDL-C) is a major Cardiovascular (CV) risk factor. Accumulating evidence supports a linear association between LDL-C levels and CV risk. However, the lower limit of LDL-C that might offer CV benefits without any safety concerns is still a topic of debate.
OBJECTIVE: The purpose of this review is to present the safety of reducing LDL-C to low levels as it comes from major lipid-lowering drug studies, and to discuss data on several safety events that have been associated with low LDL-C levels.
METHODS: A comprehensive literature search was performed to identify available data from clinical studies evaluating the association of low LDL-C with safety outcomes.
RESULTS: Several large trials have evaluated the safety or reducing LDL-C to levels lower than 50 mg/dl or even lower than 25 mg/dl, more commonly with the use of a combination of statins with ezetimibe or proprotein convertase subtilisin kexin 9 inhibitors. In almost all trials, CV benefits were observed with LDL-C levels of 50 mg/dl or less compared with higher levels. In terms of safety, reduction of LDL-C to such levels was not associated with any significant adverse event. Of importance, cancer and hemorrhagic stroke incidences were not increased in patients attaining LDL-C lower than 40-50 mg/dl. Data regarding the impact of lowering LDL-C with neurocognitive disorders are contradictory; nevertheless, most studies stand in favor of neurocognitive safety with LDL-C reductions to low levels.
CONCLUSION: Achieving an LDL-C of 40-50 mg/dl seems to be safe, and importantly might offer CV beneficial effects. Data for attaining levels below 25 mg/dl is limited, however in favor of such reductions. Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.

Entities:  

Keywords:  Low-density lipoprotein cholesterol; PCSK9 inhibitors; cancer; cardiovascular disease; safety; statins.

Mesh:

Substances:

Year:  2018        PMID: 30295187     DOI: 10.2174/1381612824666181008110643

Source DB:  PubMed          Journal:  Curr Pharm Des        ISSN: 1381-6128            Impact factor:   3.116


  2 in total

Review 1.  Lipid-lowering Drugs and Neurocognitive Function: A Systematic Review.

Authors:  Georgios Kyriakos; Lourdes Victoria Quiles-SÁnchez; Evangelos Diamantis; Paraskevi Farmaki; Nikolaos Garmpis; Christos Damaskos; Spyridon Savvanis; Alexandros Patsouras; Athanasia Stelianidi; Errika Voutyritsa; Vasiliki E Georgakopoulou; Anna Garmpi
Journal:  In Vivo       Date:  2020 Nov-Dec       Impact factor: 2.155

2.  Challenges and Opportunities for Nucleic Acid Therapeutics.

Authors:  David R Corey; Masad J Damha; Muthiah Manoharan
Journal:  Nucleic Acid Ther       Date:  2021-12-17       Impact factor: 5.486

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.